Leen Kawas Net Worth

The estimated Net Worth of Leen Kawas is at least $2.15 Milhão dollars as of 31 October 2023. Leen Kawas owns over 24,332 units of Athira Pharma stock worth over $2,151,802 and over the last 4 years Leen sold ATHA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leen Kawas ATHA stock SEC Form 4 insiders trading

Leen has made over 1 trades of the Athira Pharma stock since 2023, according to the Form 4 filled with the SEC. Most recently Leen bought 24,332 units of ATHA stock worth $6,326 on 31 October 2023.

The largest trade Leen's ever made was buying 24,332 units of Athira Pharma stock on 31 October 2023 worth over $6,326. On average, Leen trades about 12,166 units every 0 days since 2021. As of 31 October 2023 Leen still owns at least 4,391,432 units of Athira Pharma stock.

You can see the complete history of Leen Kawas stock trades at the bottom of the page.

What's Leen Kawas's mailing address?

Leen's mailing address filed with the SEC is 1900 AVENUE OF THE STARS, #1000, , LOS ANGELES, CA, 90067.

Insiders trading at Athira Pharma

Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic..., eJoseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.

What does Athira Pharma do?

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Complete history of Leen Kawas stock trades at Eiger BioPharmaceuticals Inc e Athira Pharma

Athira Pharma executives and stock owners

Athira Pharma executives and other stock owners filed with the SEC include:

• Dr. Hans Moebius,
  Chief Medical Officer
• Glenna K. Mileson,
  Chief Financial Officer
• Dr. Kevin Church Ph.D.,
  Exec. VP of Research
• Mark F. Worthington J.D.,
  Gen. Counsel & Corp. Sec.
• Julie Rathbun,
  Head of Investor Relations
• Robert Renninger,
  Director of Accounting & Reporting
• Rachel P. Lenington M.B.A.,
  Chief Operating Officer
• Dr. Mark J. Litton M.B.A., MBA, Ph.D.,
  Pres, CEO & Director
• James A Johnson,
  
• Kelly A Romano,
  
• Rachel Lenington,
  COO and CDO
• Michael A. Panzara,
  
• Kevin Church,
  CHIEF SCIENTIFIC OFFICER
• Advisors Llcperceptive Life...,
  
• Investments, Lpwong Roderic...,
  
• Martin Javier San,
  CHIEF MEDICAL OFFICER
• John M Jr Fluke,
  
• Advisors Llcperceptive Life...,
  
• Barbara Kosacz,
  
• Leen Kawas,
  President & CEO
• Hans Moebius,
  Chief Medical Officer
• Glenna Mileson,
  Chief Financial Officer
• Tadataka Yamada,
  Director
• Mark Worthington,
  GENERAL COUNSEL
• Joseph Edelman,
  
• Grant Pickering,
  
• Mark James Litton,
  President and CEO